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Abstract
Background: Pseudomonas aeruginosa is an important human opportunistic pathogen responsible for fatal nosocomial
infections worldwide, and has emerged as a relevant animal pathogen. Treatment options are dramatically decreasing,
due to antimicrobial resistance and the microorganism’s large versatile genome.
Antimicrobial resistance profiles, serotype frequency and genomic profile of unrelated P. aeruginosa isolates of veterinary
origin (n = 73), including domesticated, farm, zoo and wild animals mainly from Portugal were studied. The genomic
profile, determined by DiversiLab system (Rep-PCR-based technique), was compared with the P. aeruginosa global
population structure to evaluate their relatedness.
Results: Around 40% of the isolates expressed serotypes O6 (20.5%) and O1 (17.8%). A total of 46.6% of isolates was
susceptible to all antimicrobials tested. Isolates obtained from most animals were non-multidrug resistant (86.3%),
whereas 11% were multidrug resistant, MDR (non-susceptible to at least one agent in≥ three antimicrobial categories),
and 2.7% extensively drug resistant, XDR (non-susceptible to at least one agent in all but two or fewer antimicrobial
categories). Resistance percentages were as follows: amikacin (0.0%), aztreonam (41.1%), cefepime (9.6%), ceftazidime
(2.7%), ciprofloxacin (15.1%), colistin (0.0%), gentamicin (12.3%), imipenem (1.4%), meropenem (1.4%), piperacillin +
tazobactam (12.3%), ticarcillin (16.4%), ticarcillin + clavulanic acid (17.8%), and tobramycin (1.4%).
Animal isolates form a population with a non-clonal epidemic structure indistinguishable from the global P. aeruginosa
population structure, where no specific ‘animal clonal lineage’ was detected.
Conclusions: Serotypes O6 and O1 were the most frequent. Serotype frequency and antimicrobial resistance patterns
found in P. aeruginosa from animals were as expected for this species. This study confirms earlier results that P. aeruginosa
has a non-clonal population structure, and shows that P. aeruginosa population from animals is homogeneously scattered
and indistinguishable from the global population structure.
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Background
Pseudomonas aeruginosa is an infectious bacterial species,
with a world-wide dispersion, capable to infect and pro-
mote disease in different tissues [1], and responsible for re-
markable morbidity and mortality rates in humans [2].
P. aeruginosa is a ubiquitous bacterial species, with an
exceptional capacity to adapt to different aquatic and
terrestrial ecological niches [3, 4]. Its high adaptability is
in part explainable by its metabolic versatility [4–6]. This
opportunistic bacterium migrates from its natural envir-
onment, colonizing and infecting a wide range of organ-
isms [5, 6], including plants [7] and different animals,
such as fruit flies [8], waxmoth [9], zebrafish [10] and
mammals [11, 12].
In veterinary medicine, P. aeruginosa is responsible
for a large variety of infections such as ocular infec-
tions [13], mastitis [14, 15], discospondylitis [16], oti-
tis [17, 18], pyoderma [19], ulcerative keratitis [20],
urinary tract infections [21] and incision, joint, inva-
sive device and wound infections [22]. The most
imminent problems are otitis externa in dogs, mastitis
in cattle, dermatitis in rabbits and fleece rot in sheep.
However, the importance of animal infections caused
by P. aeruginosa has been disregarded due to the low
detection of animal clinical cases [23].
Overall, infections caused by P. aeruginosa are hard to
treat because this bacterium shows intrinsic and ac-
quired resistance to different antimicrobial compounds
[6]. It has been argued that the presence of specific outer
membrane proteins involved in efflux transport systems
or affecting cell permeability may explain the intrinsic
resistance of P. aeruginosa to antimicrobials [24–26].
P. aeruginosa strains are also able to express a wide
variety of acquired resistance mechanisms, including the
production of β-lactamases and carbapenemases [14],
mainly due to mutations in chromosomal resistance
genes or acquisition of resistance genes from other
bacteria through plasmids [18]. Moreover, resistance
transmission from humans to animals has been ac-
knowledged [27, 28].
Different studies have been consensual about the fact
that P. aeruginosa clinical isolates are indistinguishable
from the ones from the environment, either genotypi-
cally, chemotaxonomically, or functionally [5, 29, 30]. In
order to understand the global population structure,
clinical and environmental isolates collected around the
world were recently analyzed [4, 5]. Authors concluded
that P. aeruginosa has an epidemic population structure,
which is non-clonal. There are no specific P. aeruginosa
clones related with specific diseases, habitat or animal
species [5, 23].
The objective of this study was to characterize the
antimicrobial resistance patterns, serotype frequency,
and genomic profile of a collection of P. aeruginosa
isolates from a wide variety of animal species with
different kinds of infections, from different geographic
regions of Portugal. A rapid and accurate genotyping
method based on Rep-PCR, the DiversiLab system,
was used and the genomic profile was then compared




In this study, a total of 73 P. aeruginosa isolates were
used, belonging to a collection of animal isolates from
the Faculty of Veterinary Medicine, Technical University
of Lisbon (Additional file 1: Table S1). Isolates were col-
lected from 2003–2012 in different geographic regions
of Portugal, except for one sea turtle isolate sampled in
Principe Island in the Gulf of Guinea. Our batch in-
cluded 50 isolates from pets [dog (n = 39), cat (n = 5),
parrot (n = 4), turtle (n = 2)], 15 from farm animals
[horse (n = 6), cow (n = 5), sheep (n = 2), pig (n = 1), goat
(n = 1)], 7 from zoo animals [seal (n = 1), dolphin (n = 2),
kangaroo (n = 2), tamarind (n = 2)] and one from a wild
free-living sea turtle.
Bacteria were isolated on Columbia blood agar (COS,
BioMérieux, Marcy-l’Etoile, France), identified through
their morphologic characteristics and biochemical profile
(API 20 NE, BioMérieux, Marcy-l’Etoile, France) and
kept frozen at -80 °C until further processing. P. aerugi-
nosa control strain ATCC 27853 was used in this study.
Molecular identification
Species identification of the isolates was confirmed using
a previously described PCR assay targeting the P. aerugi-
nosa species-specific oprI and oprL genes [24].
Serotyping
Isolates were grown overnight on Luria-Bertani agar
medium (Gibco-BRL-Life Technologies, Brussels, Belgium)
at 37 °C, after which were serotyped by slide agglutination
according to the International Antigenic Typing Scheme
(IATS) for P. aeruginosa [31], using a panel of 16 type O
monovalent antisera (Bio-Rad, Temse, Belgium). Four anti-
sera pools, each containing four antisera, were also used:
pool A (O1, O3, O4, O6); pool E (O2, O5, O15, O16); pool
C (O9, O10, O13, O14); and pool F (O7, O8, O11, O12).
Antimicrobial resistance
Antimicrobial resistance studies were performed by
using the Vitek 2 system (BioMerieux, Marcy-l’Etoile,
France) in accordance with the manufacturer’s instruc-
tions. P. aeruginosa ATCC 27853 was included as con-
trol strain. The following antimicrobials were tested:
amikacin, aztreonam, cefepime, ceftazidime, ciprofloxacin,
colistin, gentamicin, imipenem, meropenem, piperacillin
Serrano et al. BMC Veterinary Research  (2017) 13:58 Page 2 of 8
+ tazobactam, ticarcillin, ticarcillin + clavulanic acid, and
tobramycin. Antimicrobial resistance phenotypes, repre-
sented by the minimum inhibitory concentrations (MICs)
were interpreted according to CLSI guidelines: CLSI, Per-
formance Standards for Antimicrobial Disk and Dilution
Susceptibility Tests for Bacteria Isolated From Animals
[32]. The breakpoints of aztreonam, cefepime, ceftazidime,
ciprofloxacin, colistin, meropenem, piperacillin + tazobac-
tam, and tobramycin were not defined at the above CLSI,
so their MICs were interpreted using: CLSI Performance
Standards for Antimicrobial Susceptibility Testing [33].
Rep-PCR genotyping
DiversiLab system (rep-PCR) was used for isolates geno-
typing. P. aeruginosa DNA was extracted using the
UltraCleanTM Microbial DNA Isolation Kit (Mo Bio
Laboratories Inc., Solana Beach, CA) according to the
manufacturer’s instructions. DNA quantification was
measured using a NanoDrop ND-1000 spectrophotom-
eter (NanoDrop Technologies, Wilmington, DE, USA).
Then, rep-PCR was performed using PTC 200 thermo-
cycler and Pseudomonas fingerprinting kit (Bacterial
Barcodes, bioMe´rieux, Athens, GA, USA) in a total re-
action volume of 25 μl. The reaction mixture consisted
of 18 μl of rep-PCR MM1, 2.5 μl of Gene Amp 10X, 2 μl
of primer Mix, 0.5 μl of AmpliTaq DNA polymerase
(Applied Biosystems, Foster City, CA, USA) and 2 μl of
genomic DNA (25–50 ng/ml). Thermal conditions were
as follows: initial denaturation step at 94 °C for 2 min,
35 cycles including denaturation at 94 °C for 30 s, an-
nealing at 50 °C for 30 s and extension at 70 °C for 90 s,
followed by a final extension step at 70 °C for 3 min.
PCR products were analyzed using the Agilent 2100
BioAnalyzer (Agilent Technologies, Santa Clara, CA,
USA). Then, the amplified fragments (sizes from 100–
1000 bp) were electrophoretically separated using a
microfiluidic labchip. In order to monitor reproducibil-
ity, the P. aeruginosa ATCC 27853 reference strain was
used as a control in each PCR reaction and in each chip.
Electropherograms were downloaded and automatically
analyzed by the DiversiLab software (version 3.4)
(BioMerieux, Brussels, Belgium). All fingerprint patterns
were normalized, then, the Pearson correlation coeffi-
cient was used in order to calculate the distance matri-
ces among all samples. Based on UPGMA and
multidimensional scaling, the DiversiLab software cre-
ated a customized report presenting a dendrogram, elec-
tropherograms, virtual gel images and scatter plots.
Relatedness among isolates was deduced as previously
described [34]: isolates showing similarity levels above
95% were considered as linked, while isolates with simi-
larity levels below 95% were considered as different.
Closely related isolates differing by a maximum of two
band classes were collapsed into one node.
Results
Molecular identification and serotype distribution
Both target genes used in rep-PCR (oprI and oprL) were
detected in all 73 P. aeruginosa isolates tested, confirm-
ing their identification as Pseudomonas aeruginosa.
Isolates were serotyped, being observed that most iso-
lates belonged to serotypes O6 (20.5%), O1 (17.8%), O11
(9.6%), O3 (5.5%) and O9 (5.5%) (Table 1). Isolates be-
longing to serotypes O4, O10, O15 and O12 were also
detected, but at a lower percentage. PA isolates (strains
that polyagglutinate in pools E (O2 +O5 +O15 + O16)
and F (O7, O8, O11, O12), but not in the individual
antisera) were 12.3%. Nine isolates (12.3%) were classi-
fied as NT/NA: NT (Non Typeable strains which are
polyagglutinating), NA (strains that do Not Agglutinate
in any pool or individual antiserum) (Table 1).
Antimicrobial resistance
A total of 46,6% of isolates was susceptible to all antimi-
crobials tested. Table 2 summarizes the frequency of re-
sistant isolates for all antimicrobials tested, where
intermediate isolates are also classified as resistant (low-
level resistance). Resistance to aztreonam (41.1%) was
the highest. Resistance to ciprofloxacin (15.1%), pipera-
cillin + tazobactam (12.3%), ticarcillin (16.4%) and ticar-
cillin + clavulanic acid (17.2%), was between 10% and
20%. Resistance was lowest for cefepime (9.6%), ceftazi-
dime (2.7%), imipenem (1.4%), gentamicin (12.3%), mer-
openem (1.4%), and tobramycin (1.4%). All isolates were
susceptible to amikacin and to colistin (Table 2).
The number of isolates with high-level resistance is
higher than the number of isolates with low-level resist-
ance (intermediate) (Table 2).














Serotypes with a percentage of more than 5% are expressed in boldface
NT, Non Typeable strains which are polyagglutinating; PA, strains that
PolyAgglutinate in pools E (O2 + O5 + O15 + O16) and F (O7, O8, O11, O12),
but not in the individual antisera; NA, strains that do Not Agglutinate in any
pool or individual antiserum
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The distribution of antimicrobial resistance per
serotype was as follows: serotype O1 isolates were
resistant to aztreonam (46.2%), cefepime (7.7%), cipro-
floxacin (7.7%), gentamicin (7.7%), piperacillin + tazo-
bactam (15.4%), ticarcillin (15.4%), and ticarcillin +
clavulanic acid (15.4%); serotype O6 isolates were re-
sistant to aztreonam (26.7%), ciprofloxacin (20.0%),
gentamicin (6.7%), ticarcillin (13.3%), and ticarcillin +
clavulanic acid (13.3%). These two serotypes, repre-
senting 38% of animal isolates, are in accordance to
the total results, except the fact that serotype O6 was
fully susceptible to the two cephalosporins tested,
whereas the total resistance for cephalosporins was
2.7% (ceftazidime) and 9.6% (cefepime).
Multidrug resistant (MDR) isolates are non-susceptible
to at least one agent in ≥ three antimicrobial categories,
and extensively drug resistant (XDR) isolates non-
susceptible to at least one agent in all but two or fewer
antimicrobial categories [35]. According to Magiorakos
AP et al., 2012 [33], ticarcillin is not used to define
MDR and XDR isolates, thus it was not used to define
MDR and XDR isolates in this study. Isolates obtained
from most animals were non-multidrug resistant (nor
MDR, nor XDR) (86.3%). Only 2.7% of the isolates were
XDR and 11.0% were MDR.
MDR was found in isolates belonging to serotypes O1,
O6, O11, O15, and to PA and NT isolates. MDR profiles
observed were as follows: aztreonam / ciprofloxacin /
ticarcillin + clavulanic acid (3/8) aztreonam / cefepime /
ticarcillin + clavulanic acid / piperacillin + tazobactam
(1/8), aztreonam / ceftazidime / ticarcillin + clavulanic
acid / piperacillin + tazobactam (1/8), aztreonam / cip-
rofloxacin / gentamicin / ticarcillin + clavulanic acid
(1/8), aztreonam / cefepime / gentamicin / ticarcillin
+ clavulanic acid / piperacillin + tazobactam (1/8), az-
treonam / cefepime / ciprofloxacin / ticarcillin + cla-
vulanic acid / piperacillin + tazobactam (1/8).
The two XDR isolates were obtained only from dogs.
One isolate expressed serotype O12 and was susceptible
to only one antimicrobial category (polymyxin) and non-
susceptible to at least one agent in all other antimicro-
bial categories (including aminoglycosides, as it was
non-susceptible to gentamicin). The other XDR isolate,
was a PA isolate fully susceptible to two antimicrobial
categories (carbapenems and polymyxin) and non-
susceptible to at least one agent in all other antimi-
crobial categories (including cephalosporins, as it was
non-susceptible to cefepime, and aminoglycosides, as it
was non-susceptible to gentamicin).
Genotyping
Fully automated rep-PCR (DiversiLab system) was used
as a rapid method to genetically analyze the population
structure of P. aeruginosa. The total genome profile was
determined by rep-PCR and combined with former data
from clinical (animal and human) and environmental P.
aeruginosa isolates collected across the world, previously
studied through a polyphasic approach consisting of three
outer membrane (lipo)protein gene sequences (oprI, oprL
and oprD), amplified fragment length polymorphism,
serotype and pyoverdine type [4].
Genotyping with rep-PCR did not show any animal
specific cluster, as showed in Fig 1. The dendrogram in-
cluded a total of 151 P. aeruginosa isolates: 73 from this
study, and 5 isolates which were not fully characterized
from animals collected in Portugal (these 78 are delin-
eated in blue), and 73 P. aeruginosa isolates from clinic
(animal and human) and environmental samples from a
previous study [4]. Considering a similarity of ≥80%
clusters obtained included isolates from all origins: ani-
mal, human and environmental (Fig. 1). In fact, all ani-
mal isolates from this study, including the 78 animal
clinical isolates collected from 2003–2012 in Portugal
and the one sea turtle isolate sampled in the Gulf of
Guinea, were homogeneously scattered in the global
P. aeruginosa population structure previously depicted
by Pirnay et al., (2002) [4].
Discussion
Rep-PCR is a rapid method for bacterial genome finger-
printing, based on highly conserved repetitive sequence
elements [repetitive extragenic palindromic (REP) se-
quence] within bacterial genomes, which are amplified
by PCR, allowing the analyses of strain-specific patterns
[36]. DiversiLab system used in our study is more





Amikacin ≤16 - ≥64 0.0 0.0 0.0
Aztreonam ≤8 - ≥32 15.1 (11) 26.0 (19) 41.1 (30)
Cefepime ≤8 - ≥32 0.0 9.6 (7) 9.6 (7)
Ceftazidime ≤8 - ≥32 0.0 2.7 (2) 2.7 (2)
Ciprofloxacin ≤1 - ≥4 15.1 (11) 0.0 15.1 (11)
Colistin ≤2 - ≥8 0.0 0.0 0.0
Gentamicin ≤4 - ≥16 2.7 (2) 9.6 (7) 12.3 (9)
Imipenem ≤4 - ≥16 1.4 (1) 0.0 1.4 (1)
Meropenem ≤2 - ≥8 1.4 (1) 0.0 1.4 (1)
Piperacillin +
tazobactam
≤16/4 - ≥128/4 1.4 (1) 11.0 (8) 12.3 (9)
Ticarcillin ≤64 - ≥128 16.4 (12) 0.0 16.4 (12)
Ticarcillin + clavulanic
acid
≤64/2 - ≥128/2 17.8 (13) 0.0 17.8 (13)
Tobramycin ≤4 - ≥16 1.4 (1) 0.0 1.4 (1)
aHigh, high-level resistant; bLow, low-level resistant (Intermediate)
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reproducible than standard rep-PCR method, as the ana-
lysis is fully automated [37].
Multilocus sequence typing (MLST) is a strain-typing
system that focuses exclusively on seven conserved
housekeeping genes. The analysis of these genes, less
likely to undergo horizontal gene transfer because of se-
lective neutrality, provides a more accurate imprint of
the recombination effect [5, 38]. The combination of
alleles at the seven loci provided an allelic profile, or se-
quence type (ST). The relatedness between isolates is de-
termined through a dendrogram from the matrix of
pairwise differences between STs [39]. These data can be
used in different aspects of evolutionary biology,
whether to understand the evolution of genetic lineages
or to estimate the relative contribution of recombination
and single mutations in bacterial species [40]. MLST is
therefore suitable for phylogenetic analysis enabling to
track the global clonal history of the species with high
accuracy [38]. Another advantage of MLST is that se-
quence data are portable between laboratories enabling
to compare data from different geographic areas [40].
Although MLST is highly informative, the genetic vari-
ation indexed by MLST accumulates slowly, being more
useful for long term epidemiological studies [39]. It has
a limited resolution when applied to closely related
stains [37]. On the other hand, DiversiLab is efficient to
detect subtle genomic differences when applied to very
closely related strains, being more useful for short term
studies and outbreaks investigation [37].
Although we did not perform MLST, DiversiLab
system results allow concluding that all animal isolates
from this study were homogeneously scattered in the
global P. aeruginosa population structure (Fig. 1), con-
firming earlier results that P. aeruginosa has a non-
clonal population structure [4].
Our results are in accordance with the previous study
by Pirnay et al., (2002) [4], in which a total of 73 P. aeru-
ginosa clinical and environmental isolates collected
worldwide presented predominantly the following sero-
types: O1 (12.3%), O6 (10.9%), O11 (15.1%). The only
exception was for serotype O12, which was less frequent
in our study (2.7% versus 9.6%) (Table 1) [4]. Our results
also agree with a recent study [41], regarding P. aeruginosa
isolates from nosocomial pneumonia cases from several
hospitals located in different countries. In both studies, fre-
quency of serotypes O6, O11, O1, O4, O12 and O15 was
Fig. 1 Normalized rep-PCR patterns and dendrogram for a total of 151 P.
aeruginosa isolates: 73 P. aeruginosa isolates of this study plus 5 animal
isolates not fully characterized (all delineated in blue), and 73 P. aeruginosa
isolates from clinic (animal and human) and environmental origin from a
previous study [4]. DiversiLab dendrogram based on UPGMA and Pearson
correlation coefficient. Percentages of similarity are shown below
the dendrogram
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similar, as also observed for not typeable isolates. By the
contrary, different results were observed regarding serotype
O10 (4.1% versus 9.8%), and we were not able to detect se-
rotypes O2, O7 and O8 (Table 1).
P. aeruginosa is generally resistant against a wide
spectrum of antimicrobial agents. Hence, only a few
agents, including some extended-spectrum β-lactams,
aminoglycosides, and fluoroquinolones are still effective
[42, 43]. Resistance patterns were typical for this species.
Near 50% of isolates was susceptible to all antimicrobials
tested (46.6%). As expected, the aminoglycosides, carba-
penems, cephalosporins, and polymyxin studied had also
low resistance levels, maximum 12.3% (Table 2), thus
amikacin, cefepime, ceftazidime, colistin, gentamicin,
imipenem, meropenem, and tobramycin are generally ef-
fective in animals. Of notice that carbapenems are critic-
ally important antimicrobials and should be reserved for
human use. The latest European Medicines Agency re-
port, published in October 2015, shows that sales of an-
timicrobials for use in animals in Europe fell by
approximately 8% between 2011 and 2013. However,
there are notably differences between countries: 11
countries have decreased the sales of veterinary anti-
microbial agents, whereas 6 countries including Portugal
increased [44]. The greater percentages of sales for food-
producing animals, including horses, in mg per popula-
tion correction unit (mg/PCU), of the various veterinary
antimicrobial classes, in Portugal, in 2013, were tetracy-
clines (39.2), penicillins (16.9), macrolides (12.4), poly-
myxins (10.1) [44].
There was a high resistance rate among animal isolates
tested against monobactam aztreonam (41.1%). Resistance
rates of penicillins [ticarcillin (16.4%), ticarcillin + clavula-
nic acid (17.8%), piperacillin + tazobactam (12.3%)] and
the fluoroquinolone ciprofloxacin (15.1%) were inferior to
20% (Table 2).
The higher resistance rates among those critical antimi-
crobials should most probably result from intrinsic anti-
microbial resistance traits of P. aeruginosa, such as low
cell wall permeability, and its capacity to express acquired
resistance mechanisms [14], and to a lesser degree to vet-
erinary medicine antimicrobial consumption. It should be
addressed that probably this collection of strains from ani-
mals are probably more resistant than in general, since
often specimens are collected from chronic cases.
Near 14% of isolates were MDR and XDR (13.7%),
pointing to the importance of the transmission of anti-
microbial resistance genes in P. aeruginosa from ani-
mals. The antimicrobial resistance is a priority to FAO/
OIE/WHO under the concept “One Health”. Is crucial
to include an international perspective in any politics
about antimicrobial resistance. To decrease antimicro-
bial resistance in veterinary isolates, it is important to
continue to implement responsible-use campaigns, to
raise awareness of the threat of antimicrobial resist-
ance, and to restrict its use and targets [44]. In the
future, a safe and gradual implementation of alterna-
tives to antimicrobials will be crucial to face anti-
microbial resistance [45].
Interestingly, the XDR isolate only susceptible to ami-
kacin, colistin, and tobramycin, was isolated from a dog
with an infected surgical wound and was serotyped as
O12 which is a serotype associated with human XDR
clonal-cluster [5, 46]. Based on this observation, can one
can speculate the possibility of resistance transmission
from humans to animals [27, 28].
Conclusions
The reported data shows that serotype frequency and the
resistance patterns of P. aeruginosa collected from animals
were typical for this species. The intrinsic resistance
mechanism of P. aeruginosa should explain the presence
of multidrug profiles and the high resistance rates ob-
served in some critical antimicrobials. This study confirms
earlier results that P. aeruginosa has a non-clonal popula-
tion structure, and demonstrates the similarity between
environmental and clinical isolates from animals and
humans. They are all part of the global P. aeruginosa
population and form a non-clonal epidemic structure. No
specific ‘animal clonal lineage’ could be detected.
Additional file
Additional file 1: Table S1. Overview of the characteristics, serotyping
and antimicrobial susceptibility of P. aeruginosa strains. (DOCX 30 kb)
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